Sana Biotechnology, Inc.

NASDAQ:SANA

Biotechnology

Healthcare
$1.85 +1.23%

+$0.04 today

Market cap
$554.32M
Beta
2.16
P/E (TTM)
-3.5
EPS (TTM)
-$0.87
52W Low $2.58High $6.55

Volume 2.66M

Average 3.76M

SANA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Sana Biotechnology, Inc.NASDAQ: SANA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $2.39M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $2.39M.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $2.39M or moves back toward the trailing-twelve-month quarterly average of $597.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.39M— QoQ
Last fiscal yearDec 2025
$12.75M— YoY
LTMMar 2026
$2.39M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
12.75M USD
Year-over-year change
—

Cost of Revenue vs competitors

How SANA compares with its peers on the latest reported figures

  • SANA's LTM Mar 2026 cost of revenue of $2.39M is the 7th highest of the 11 companies compared; the peer median is $31.22M.
SANA Competitors Peer median
Cost of Revenue for SANA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M +63.0%+84.1%43.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$167.7M -26.7%+28.1%253.7%
CRSPCRISPR Therapeutics AGLTM Sep 2026$165.86M -3.5%+28.3%658.9%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M -23.8%-4.7%—
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M -62.0%-2.1%515.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$29.86M ———
SANASana Biotechnology, Inc.LTM Mar 2026$2.39M ———
DTILPrecision BioSciences, Inc.LTM Mar 2026$1.37M ——3.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$897K -97.7%-57.2%3.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K +2.6%——
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 —-58.5%0.0%
Peer median (excluding SANA) $31.22M-23.8%-2.1%43.0%

Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000012.75M
Gross Profit0000(12.75M)
Gross Margin—————
Research & Development306.5M201M219.84M208.68M131.98M
Selling, General & Admin50.41M71.56M73.3M64.04M44.3M
Operating Expenses356.91M272.56M293.14M272.72M178.21M
Depreciation & Amortization11.07M15.63M24.56M17.39M12.75M
EBITDA(344.86M)(253.85M)(258.7M)(249.37M)(231.42M)
EBITDA Margin—————
Operating Income(356.91M)(272.56M)(293.14M)(272.72M)(190.96M)
Operating Margin—————
Interest Income676K3.76M9.94M10.47M3.85M
Interest Expense00000
Other Income / Expenses981K3.09M9.89M5.96M(53.21M)
Income Before Tax(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Net Margin—————
EPS (Basic)(2.14)(1.43)(1.46)(1.16)(0.96)
EPS (Diluted)(2.14)(1.43)(1.46)(1.16)(0.96)
Weighted Avg Shares166.43M188.34M194.54M230.89M253.23M
Weighted Avg Shares (Diluted)166.43M188.34M194.54M230.89M253.23M

Sana Biotechnology, Inc.

NASDAQ:SANA

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.